Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Jan. 25 '25)

Image
By G.M.

 


    Ann Intern Med

  1. VALE CL, Godolphin PJ, Fisher DJ, Higgins JPT, et al
    Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
    Ann Intern Med. 2024 Dec 24. doi: 10.7326/ANNALS-24-00800.
    PubMed         Abstract available


    Antiviral Res

  2. GAO M, Zhang Z, Yao G, Zhang L, et al
    Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
    Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060.
    PubMed         Abstract available

  3. MERCURI FA, Anderson GP, Miller BE, Demaison C, et al
    Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections.
    Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063.
    PubMed         Abstract available

  4. SHANNON A, Canard B
    Nucleotide analogues and mpox: Repurposing the repurposable.
    Antiviral Res. 2024;234:106057.
    PubMed         Abstract available


    Biochemistry

  5. HANSON Q, Hu X, Pal S, Recabo K, et al
    A High-Throughput Screening Pipeline to Identify Methyltransferase and Exonuclease Inhibitors of SARS-CoV-2 NSP14.
    Biochemistry. 2025;64:419-431.
    PubMed         Abstract available


    Cell

  6. SONG H, Hao T, Han P, Wang H, et al
    Receptor binding, structure, and tissue tropism of cattle-infecting H5N1 avian influenza virus hemagglutinin.
    Cell. 2025 Jan 22:S0092-8674(25)00048-0. doi: 10.1016/j.cell.2025.
    PubMed         Abstract available


    Epidemiol Infect

  7. BROWN J, Mook P, Vanhaverbeke M, Gimma A, et al
    Case-only analysis of routine surveillance data: detection of increased vaccine breakthrough infections with SARS-CoV-2 variants in Europe.
    Epidemiol Infect. 2025;153:e16.
    PubMed         Abstract available

  8. ARASHIRO T, Solante R, Sayo AR, Garcia RM, et al
    Factors associated with COVID-19 in-hospital death and COVID-19 vaccine effectiveness against COVID-19 hospitalization in the Philippines during pre-omicron and omicron period: A case-control study (MOTIVATE-P study).
    Epidemiol Infect. 2024;153:e18.
    PubMed         Abstract available


    Pediatrics

  9. GAVIRIA-AGUDELO C, Yonts AB, Kimberlin DW, O'Leary ST, et al
    October 2024 ACIP Meeting Update: Influenza, COVID-19, RSV and Other Vaccines.
    Pediatrics. 2025 Jan 24. doi: 10.1542/peds.2024-069926.
    PubMed         Abstract available


    PLoS Comput Biol

  10. CHERIAN P, Kshirsagar J, Neekhra B, Deshkar G, et al
    BharatSim: An agent-based modelling framework for India.
    PLoS Comput Biol. 2024;20:e1012682.
    PubMed         Abstract available


    PLoS Med

  11. ODD D, Stoianova S, Williams T, Fleming P, et al
    Child mortality in England after national lockdowns for COVID-19: An analysis of childhood deaths, 2019-2023.
    PLoS Med. 2025;22:e1004417.
    PubMed         Abstract available

  12. PETER RS, Nieters A, Gopel S, Merle U, et al
    Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.
    PLoS Med. 2025;22:e1004511.
    PubMed         Abstract available


    PLoS One

  13. BURRELL R, Saravanos GL, Kesson A, Leung KC, et al
    Respiratory virus detections in children presenting to an Australian paediatric referral hospital pre-COVID-19 pandemic, January 2014 to December 2019.
    PLoS One. 2025;20:e0313504.
    PubMed         Abstract available

  14. VALACHOVIC EL, Shishova E
    Seasonal and periodic patterns in US COVID-19 mortality using the Variable Bandpass Periodic Block Bootstrap.
    PLoS One. 2025;20:e0317897.
    PubMed         Abstract available

  15. MASUMOTO Y, Kawasaki H, Matsuyama R, Tsunematsu M, et al
    Class-specific school closures for seasonal influenza: Optimizing timing and duration to prevent disease spread and minimize educational losses.
    PLoS One. 2025;20:e0317017.
    PubMed         Abstract available

  16. SCACCABAROZZI D, Ponti J, Gioria S, Mehn D, et al
    Atmospheric pressure plasma jet for respiratory face masks decontamination and re-use: Considerations on microbiological efficacy, material impact and product lifecycle.
    PLoS One. 2025;20:e0313041.
    PubMed         Abstract available

  17. AGUILAR-PALMA SK, McCoy TP, Mann-Jackson L, Alonzo J, et al
    Characteristics influencing COVID-19 testing and vaccination among Spanish-speaking Latine persons in North Carolina.
    PLoS One. 2025;20:e0317794.
    PubMed         Abstract available

  18. COMAKLI DUVAR N, Kabakus AK, Iyit N, Alkan O, et al
    A study on the determination of the factors affecting the happiness levels of older individuals during the COVID-19 pandemic in Turkish society.
    PLoS One. 2025;20:e0316000.
    PubMed         Abstract available

  19. ARGHAL R, Rubin H, Saeedi Bidokhti S, Sarkar S, et al
    Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization.
    PLoS One. 2025;20:e0316294.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. DUCH RM, Loewen P, Robinson TS, Zakharov A, et al
    Governing in the face of a global crisis: When do voters punish and reward incumbent governments?
    Proc Natl Acad Sci U S A. 2025;122:e2405021122.
    PubMed         Abstract available

  21. KIRBY MB, Petersen BM, Faris JG, Kells SP, et al
    Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive.
    Proc Natl Acad Sci U S A. 2025;122:e2412787122.
    PubMed         Abstract available

  22. FERRERI LM, Seibert B, Caceres CJ, Patatanian K, et al
    Dispersal of influenza virus populations within the respiratory tract shapes their evolutionary potential.
    Proc Natl Acad Sci U S A. 2025;122:e2419985122.
    PubMed         Abstract available


    Vaccine

  23. LIAO Z, Deng L, Luo J, Shi M, et al
    Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
    Vaccine. 2025;48:126757.
    PubMed         Abstract available

  24. TRANTER I, Judd D, Stickley M, Vasant B, et al
    Promoting aged care COVID-19 and influenza vaccination through education of Australian residential aged care staff: A mixed methods project evaluation.
    Vaccine. 2025;48:126742.
    PubMed         Abstract available

  25. ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al
    A framework for monitoring RSV prevention product effectiveness in the United States.
    Vaccine. 2025;45:126633.
    PubMed         Abstract available

  26. GIERSING B, Mo AX, Hwang A, Baqar S, et al
    Meeting summary: Global vaccine and immunization research forum, 2023.
    Vaccine. 2025;46:126686.
    PubMed         Abstract available

  27. DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al
    Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry.
    Vaccine. 2025;46:126682.
    PubMed         Abstract available

  28. NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al
    Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
    Vaccine. 2024;46:126651.
    PubMed         Abstract available

  29. GRIMES DR
    Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
    Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657.
    PubMed         Abstract available

  30. SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al
    Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
    Vaccine. 2024;45:126615.
    PubMed         Abstract available

  31. SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
    Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
    Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
    PubMed         Abstract available

  32. CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al
    Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study.
    Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581.
    PubMed         Abstract available

  33. BODY A, Lal L, Srihari S, MacIntyre CR, et al
    Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
    Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547.
    PubMed         Abstract available

  34. SLAMANIG S, Lemus N, Lai TY, Singh G, et al
    A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
    Vaccine. 2024;45:126586.
    PubMed         Abstract available

  35. KARACHALIOU M, Espinosa A, Farre X, Blay N, et al
    Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.
    Vaccine. 2024;45:126591.
    PubMed         Abstract available

  36. CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al
    Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
    Vaccine. 2025;45:126582.
    PubMed         Abstract available

  37. PERRIER Q, Noble J, Bonadona A, Augier C, et al
    Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
    Vaccine. 2024;45:126617.
    PubMed         Abstract available

  38. SUN JW, Dodge LE, Kim EJ, Zhou L, et al
    Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
    Vaccine. 2024;45:126629.
    PubMed         Abstract available

  39. MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al
    Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
    Vaccine. 2024;45:126631.
    PubMed         Abstract available

  40. EURICH DT, Weaver O, McDermott C, Soprovich A, et al
    Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.
    Vaccine. 2025;45:126614.
    PubMed         Abstract available

  41. YANG J, Yao YL, Lv XY, Geng LH, et al
    The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.
    Vaccine. 2024;45:126635.
    PubMed         Abstract available

  42. MYEMBA DT, Smets L, Sunguya BF, Vandaele N, et al
    Challenges and strategies for sustainable and resilient immunization systems in sub-Saharan Africa: A comprehensive scoping review.
    Vaccine. 2025;45:126639.
    PubMed         Abstract available

  43. CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al
    "They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
    Vaccine. 2024;45:126618.
    PubMed         Abstract available

  44. GEBRECHERKOS Y, Hodgson D
    Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom.
    Vaccine. 2025;45:126647.
    PubMed         Abstract available

  45. SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al
    Trust in government vaccine recommendations during the Covid-19 pandemic in Singapore: A longitudinal survey study.
    Vaccine. 2024;45:126643.
    PubMed         Abstract available


    Virology

  46. NI M, Lin S, Shao Y, Tang J, et al
    Enteric pathogenicity characterization of emerging parainfluenza virus 5 in western China.
    Virology. 2025;604:110409.
    PubMed         Abstract available

  47. HASSAN MSH, Sharif S
    Immune responses to avian influenza viruses in chickens.
    Virology. 2025;603:110405.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »